Evidence map›Paper›PMID 25199993›Full record

ArticleNMR in biomedicine2014

HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer.

Alan S Wang, Alessia Lodi, Lee B Rivera, Jose L Izquierdo-Garcia, Matthew A Firpo, Sean J Mulvihill, Margaret A Tempero, Gabriele Bergers, Sabrina M Ronen

Open access · greenAbstract read
In one paragraph

Article in NMR in biomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Fingerprinting the Metabolic and Lipidomic Landscapes of Pancreatic Ductal Adenocarcinoma with MALDI Imaging.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Use of Nuclear Magnetic Resonance (NMR) to Study Cancer Metabolism.Advances in experimental medicine and biology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Rapid diagnosis and tumor margin assessment during pancreatic cancer surgery with the MasSpec Pen technology.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Alan S WangDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Alessia Lodi
Lee B Rivera
Jose L Izquierdo-Garcia
Matthew A Firpo
Sean J Mulvihill
Margaret A Tempero
Gabriele Bergers
Sabrina M Ronen
University of California, San Francisco · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of California System · USHuntsman Cancer Institute · USUniversity of Utah · US

Funding

Multipotential mesenchymal stem cell-like cells in pancreatic tumorigenesisR01CA154383 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGERS, GABRIELE · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA154383
6 · The paper itself

Abstract

The prognosis for patients with pancreatic cancer is extremely poor, as evidenced by the disease's five-year survival rate of ~5%. New approaches are therefore urgently needed to improve detection, treatment, and monitoring of pancreatic cancer. MRS-detectable metabolic changes provide useful biomarkers for tumor detection and response-monitoring in other cancers. The goal of this study was to identify MRS-detectable biomarkers of pancreatic cancer that could enhance currently available imaging approaches. We used (1) H high-resolution magic angle spinning MRS to probe metabolite levels in pancreatic tissue samples from mouse models and patients. In mice, the levels of lipids dropped significantly in pancreata with lipopolysaccharide-induced inflammation, in pancreata with pre-cancerous metaplasia (4 week old p48-Cre;LSL-Kras(G12D) mice), and in pancreata with pancreatic intraepithelial neoplasia, which precedes invasive pancreatic cancer (8 week old p48-Cre LSL-Kras(G12D) mice), to 26 ± 19% (p = 0.03), 19 ± 16% (p = 0.04), and 26 ± 10% (p = 0.05) of controls, respectively. Lactate and taurine remained unchanged in inflammation and in pre-cancerous metaplasia but increased significantly in pancreatic intraepithelial neoplasia to 266 ± 61% (p = 0.0001) and 999 ± 174% (p < 0.00001) of controls, respectively. Importantly, analysis of patient biopsies was consistent with the mouse findings. Lipids dropped in pancreatitis and in invasive cancer biopsies to 29 ± 15% (p = 0.01) and 26 ± 38% (p = 0.02) of normal tissue. In addition, lactate and taurine levels remained unchanged in inflammation but rose in tumor samples to 244 ± 155% (p = 0.02) and 188 ± 67% (p = 0.02), respectively, compared with normal tissue. Based on these findings, we propose that a drop in lipid levels could serve to inform on pancreatitis and cancer-associated inflammation, whereas elevated lactate and taurine could serve to identify the presence of pancreatic intraepithelial neoplasia and invasive tumor. Our findings may help enhance current imaging methods to improve early pancreatic cancer detection and monitoring.

Indexed as

AnimalsCarcinoma, Pancreatic DuctalEarly DiagnosisGenes, rasHumansLactatesLipidsLipopolysaccharidesMagnetic Resonance SpectroscopyMiceMice, Inbred C57BLMice, Mutant StrainsPancreasPancreatic NeoplasmsPancreatitisPrecancerous ConditionsLactatesLipidsLipopolysaccharidesTaurineHR-MASlactatelipidpancreatic cancerPDACtaurine

Identifiers

PMID25199993
PMCPMC5554431
OpenAlexW1948988765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.